Léim ar aghaidh chuig an bpríomhábhar
Gnáthamharc

Vaccination Programme

Dáil Éireann Debate, Thursday - 8 September 2022

Thursday, 8 September 2022

Ceisteanna (1603)

Fergus O'Dowd

Ceist:

1603. Deputy Fergus O'Dowd asked the Minister for Health if he will provide further details on the need to provide additional HPV vaccination supplies and options to secondary schools for those not vaccinated in the 2020-2021 term considering the figures to date which show a considerable reduction on uptake in the previous two years, in particular to ensure that students from low-income families can still avail of the vaccine where they cannot pay privately; and if he will make a statement on the matter. [42348/22]

Amharc ar fhreagra

Freagraí scríofa

The immunisation programme in Ireland is based on the advice of the National Immunisation Advisory Committee (NIAC). The committee's recommendations are based on the prevalence of the relevant disease in Ireland and international best practice in relation to immunisation.

The ages at which vaccines are recommended in the immunisation schedule are chosen by the NIAC in order to give each child the best possible protection against vaccine preventable diseases. As the HPV vaccine is preventative it is intended to be administered, if possible, before a person becomes exposed to HPV infection.

Therefore, the gender-neutral HPV vaccination programme targets all girls and boys in first year of secondary school to provide maximum coverage.

In October 2021, my Department asked the National Immunisation Advisory Committee to consider the clinical effectiveness of providing the HPV vaccine to:

- girls and boys in secondary school who were eligible to receive HPV vaccine in 1st year but who did not receive it; and

- women up to the age of 25 years who have left secondary school and who did not receive the vaccine when eligible.

I can confirm that the NIAC has submitted its advices in relation to the HPV Vaccination Programme to my Department. As part of its advices, the NIAC noted that HPV vaccination should be prioritised for unvaccinated second level students and females under the age of 25 years.

In line with that advice, I have asked the HSE to provide an opportunity for all boys and girls in secondary schools who were previously eligible to receive the HPV vaccine and who have not yet, for whatever reason, received it, to now be offered the vaccine.

I have also asked the HSE to provide options on how best to introduce a catch-up programme for young women who have now left secondary school and who did not receive the vaccine when they were eligible.

I will be in a position to outline timeframes once the HSE has completed its examination of potential implementation options.

Barr
Roinn